Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution

Abstract

Provided is a method for preventing or treating inflammation and associated states (e.g. infection, hypersensitivity, pain) by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This patent application claims the benefit of U.S. Provisional Patent Application Nos. 60 / 760,635, filed Jan. 20, 2006; 60 / 760,567, filed Jan. 20, 2006; 60 / 760,645, filed Jan. 20, 2006; and 60 / 760,557, filed Jan. 20, 2006; all of which are hereby incorporated by reference in their entireties.BACKGROUND OF THE INVENTION [0002] Inflammation is a biological response that can result from a noxious stimulus and is normally intended to remove that stimulus or ameliorate its effects. Although normally intended to promote survival, inflammation can cause damage to the host, especially in mammals. The stimulus or insult initiating inflammation can be caused by endogenous factors (e.g., an auto-antigen or irritating body fluid) or exogenous factors (e.g., a foreign body or infectious agent). [0003] Inflammation has been classified as “acute” and “chronic.” Acute inflammation is typically of relatively short duration, lasting minutes to hours and,...

AI Technical Summary

Benefits of technology

"The present invention provides a method for preventing or treating inflammation in a patient by administering a stable oxidative reductive potential (ORP) water solution. The solution can be used alone or in combination with other therapeutic agents such as antibiotics, anti-inflammatory agents, or compounds used for allergic reactions. The solution can be administered through various routes such as nasal, sinus, pharyngeal, tracheal, pulmonary, esophageal, gastric, intestinal, mesothelial, peritoneal, synovial, urinary bladder, urtheral, vaginal, uterine, fallopian, pancreatic, nervous, oral, cutaneous, and subcutaneous. The solution is stable for at least 24 hours and can be produced by electrolysis. The solution exhibits potent anti-inflammatory activity without being toxic to normal tissues and cells."

Problems solved by technology

Although normally intended to promote survival, inflammation can cause damage to the host, especially in mammals.

Increased vascular permeability also results from cellular mediators and leads to an accumulation of protein-rich fluid.

The PMNLs release toxic metabolites and proteinases that can cause tissue damage.

Acute inflammation can undergo complete resolution, lead to the formation of an abscess, result in scarring fibrosis or progress to chronic inflammation.

Chronic inflammation can result in permanent tissue damage or complete healing.

Hypersensitivity can result in significant pathology including, e.g., anaphylaxis, transplant rejection, and autoimmune diseases.

While the pro-inflammatory response is crucial for effective clearance of the pathogen or allergen, the inflammatory mediators produced cause tissue damage and inflammation.

Dysregulation of this response could induce local damage (e.g. lung fibrosis) or could lead to potentially lethal conditions like septic shock and systemic inflammatory response syndrome (SIRS) as previously mentioned.

SIRS may affect all organ systems and may lead to multiple organ dysfunction syndrome (MODS).

However, conventional anti-inflammatory therapy suffers from several drawbacks, e.g., systemic toxicity, allergic reactions, insulin resistance, hypertension, cardiac toxicity, renal toxicity, various coagulopathies and gastric erosions.

Images